7498 Results (Page 233 of 300)
Pharmaceuticals Markets Research Reports
Nigeria Liver Diseases Therapeutics Market Analysis
By 2030, it is anticipated that the Nigeria liver disease therapeutics market will reach a value of $35 Mn from $21 Mn in 2022, growing at a CAGR of 6.7 % during 2022-2030. Liver disease therapeutics in Nigeria is dominated by a few domestic pharmaceutical companies such as May & Baker Nigeria, GSK Nigeria, and Swiss Pharma Nigeria. The market in Nigeria is segmented into different types of diseases and different therapy types. Some of the major factors affecting the market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.
Netherlands Liver Diseases Therapeutics Market Analysis
By 2030, it is anticipated that the Netherlands liver disease therapeutics market will reach a value of $97 Mn from $60 Mn in 2022, growing at a CAGR of 6.2 % during 2022-2030. Liver disease therapeutics in the Netherlands is dominated by a few domestic pharmaceutical companies such as Astellas Pharma, Philips Healthcare, and Pharming Group. The liver disease therapeutics market in the Netherlands is segmented into different types of disease and different therapy types. Some of the major factors affecting the market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.
UAE Oncology Therapeutics Market Analysis
By 2030, it is anticipated that the UAE Oncology Therapeutics Market will reach a value of $1.8 Bn from $0.91 Bn in 2022, growing at a CAGR of 9.4% during 2022-2030. The Oncology Therapeutics Market in UAE is dominated by a few domestic pharmaceutical companies such as Neopharma, Medpharma, and Julphar. The Oncology Therapeutics Market in UAE is segmented into different types of cancer and different therapy type. The major risk factors associated with cancer are diet, alcohol, tobacco, air pollution, and physical inactivity. The demand for UAE Oncology Therapeutics is increasing on account of the rise in initiatives taken by the Government of the country.
Kenya Liver Diseases Therapeutics Market Analysis
By 2030, it is anticipated that the Kenya liver disease therapeutics market will reach a value of $27 Mn from $16 Mn in 2022, growing at a CAGR of 6.8% during 2022-2030. Liver disease therapeutics in Kenya is dominated by a few domestic pharmaceutical companies such as Medisel Kenya Limited, Universal Corporation, and Laborex Kenya. The liver disease therapeutics market in Kenya is segmented into different types of disease and different therapy types. Some of the major factors affecting the market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.
Belgium Liver Diseases Therapeutics Market Analysis
By 2030, it is anticipated that the Belgium liver disease therapeutics market will reach a value of $79 Mn from $51 Mn in 2022, growing at a CAGR of 5.7 % during 2022-30. Liver disease therapeutics in Belgium is dominated by a few domestic pharmaceutical companies such as Ablynx, UCB Pharma, and Galapagos. The Liver Disease Therapeutics market in Belgium is segmented into different types of disease and different therapy types. Some of the major factors affecting the Belgium liver disease therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.
Japan Oncology Therapeutics Market Analysis
By 2030, it is anticipated that the Japan Oncology Therapeutics Market will reach a value of $22.3 Bn from $11.2 Bn in 2022, growing at a CAGR of 8.9% during 2022-2030. The Oncology Therapeutics Market in Japan is dominated by a few domestic pharmaceutical companies such as Takeda Pharmaceutical, Daiichi Sankyo, and Astellas Pharma. The Oncology Therapeutics Market in Japan is segmented into different types of cancer and different therapy type. The major risk factors associated with cancer are diet, alcohol, tobacco, air pollution, and physical inactivity. The demand for Japan Oncology Therapeutics is increasing on account of the rise in initiatives taken by the Government of the country.
Italy Oncology Therapeutics Market Analysis
By 2030, it is anticipated that the Italy Oncology Therapeutics Market will reach a value of $8 Bn from $4.3 Bn in 2022, growing at a CAGR of 7.9% during 2022-2030. The Oncology Therapeutics Market in Italy is dominated by a few domestic pharmaceutical companies such as Dompe, MolMed, and Menarini. The Oncology Therapeutics Market in Italy is segmented into different types of cancer and different therapy type. The major risk factors associated with cancer are diet, alcohol, tobacco, air pollution, and physical inactivity. The demand for Italy Oncology Therapeutics is increasing on account of the rise in initiatives taken by the Government of the country.
Indonesia Oncology Therapeutics Market Analysis
By 2030, it is anticipated that the Indonesia Oncology Therapeutics Market will reach a value of $2.1 Bn from $1.1 Bn in 2022, growing at a CAGR of 8.4% during 2022-2030. The Oncology Therapeutics Market in Indonesia is dominated by a few domestic pharmaceutical companies such as Dexa Medica, Kalbe Farma, and Tempo Scan Pacific. The Oncology Therapeutics Market in Indonesia is segmented into different types of cancer and different therapy type. The major risk factors associated with cancer are diet, alcohol, tobacco, air pollution, and physical inactivity. The demand for Indonesia Oncology Therapeutics is increasing on account of the rise in initiatives taken by the Government of the country.
Spain Cardiovascular Diseases Therapeutics Market Analysis
Spain's cardiovascular disease therapeutics market is expected to witness growth from $3.13 Bn in 2022 to $5.08 Bn in 2030 with a CAGR of 6.22% for the year 2022-2030. People in Spain are becoming more aware of cardiovascular diseases and their implications, therefore, leading to the development of new and inventive therapeutic options for the treatment of cardiovascular disease in Spain. The Spain cardiovascular disease therapeutics market is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and by the end user. Pharmagenus, Ferrer, and Janssen Pharmaceuticals are the major players in the Spain cardiovascular disease therapeutics market.
Egypt Oncology Therapeutics Market Analysis
By 2030, it is anticipated that the Egypt Oncology Therapeutics Market will reach a value of $1.1 Bn from $0.51 Bn in 2022, growing at a CAGR of 9.9% during 2022-2030. The Oncology Therapeutics Market in Egypt is dominated by a few domestic pharmaceutical companies such as Pharco, EIPICO, and Amoun Pharmaceutical. The Oncology Therapeutics Market in Egypt is segmented into different types of cancer and different therapy type. The major risk factors associated with cancer are diet, alcohol, tobacco, air pollution, and physical inactivity. The demand for Egypt Oncology Therapeutics is increasing on account of the rise in initiatives taken by the Government of the country.
US Depression Therapeutics Market Analysis
The US depression therapeutics market is projected to grow from $4.2 Bn in 2022 to $5.5 Bn by 2030, registering a CAGR of 3.2% during the forecast period of 2022-30. The key players in the market include major pharmaceutical companies such as Pfizer, Inc., Eli Lilly and Company, and Johnson & Johnson, as well as smaller companies, focused on developing innovative new treatments and therapies for depression. Factors driving the growth of the US Depression Therapeutics Market include the increasing prevalence of depression, the growing acceptance of mental health issues, and the development of new and innovative treatments and therapies.
US Cardiovascular Diseases Therapeutics Market Analysis
The US Cardiovascular Disease (CVD) therapeutics market is projected to grow from $68.3 Bn in 2022 to $102.6 Bn by 2030, registering a CAGR of 5.22% during the forecast period of 2022-30. CVD is the leading cause of death in the US and affects a significant portion of the population. This high prevalence of CVD creates a large market for CVD treatments and drives demand for new and innovative therapies. Some of the key players in the US CVD therapeutics market include Pfizer, Novartis, Merck & Co., Sanofi, Bristol-Myers Squibb, and Amgen.
US ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis
The US ADHD (Attention Deficit Hyperactivity Disorder) therapeutic market is projected to grow from $12.4 Bn in 2022 to $19.1 Bn by 2030, registering a CAGR of 5.5% during the forecast period of 2022-30. ADHD is one of the most common neurodevelopmental disorders in children, with an estimated prevalence of 6-9% in the US. The rising prevalence of ADHD is driving the demand for effective treatments and contributing to the growth of the market. Some key players in the US ADHD therapeutic market include Shire (now part of Takeda Pharmaceutical Company), Pfizer Inc., Novartis International AG, Johnson & Johnson, Eli Lilly and Company, and GlaxoSmithKline plc.
US Liver Diseases Therapeutics Market Analysis
The US liver disease therapeutics market is projected to grow from $9.7 Bn in 2022 to $13 Bn by 2030, registering a CAGR of 3.7% during the forecast period of 2022-30. Liver diseases such as hepatitis, liver cancer, and NAFLD are becoming increasingly prevalent in the US population, driving demand for effective treatments. Some of the key players operating in the US liver disease therapeutics market include Gilead Sciences, Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol-Myers Squibb, and Novartis AG. These companies are investing heavily in research and development to develop new and innovative treatments for liver disease and are expected to continue to drive the growth of the market in the coming years.
US Liver Cancer Therapeutics Market Analysis
The US liver cancer therapeutics market is projected to grow from $1.2 Bn in 2022 to $3.9 Bn by 2030, registering a CAGR of 15.6% during the forecast period of 2022-30. The market for liver cancer therapeutics in the US is driven by factors such as the increasing prevalence of liver cancer, the growing demand for effective treatment options, and advancements in technology and drug development. In addition, the increasing use of combination therapies, the development of targeted therapies, and the focus on personalized medicine are also contributing to the growth of this market. The major players operating in the US liver cancer therapeutics market include pharmaceutical companies such as Bristol-Myers Squibb, Bayer Healthcare, Pfizer Inc., Eisai Co., Ltd., and F. Hoffmann-La Roche AG.
US Infectious Disease Therapeutics Market Analysis
The US infectious disease therapeutics market is projected to grow from $50.3 Bn in 2022 to $60.6 Bn by 2030, registering a CAGR of 2.35% during the forecast period of 2022-30. Antibiotics are one of the most commonly prescribed classes of drugs for infectious diseases, but the rise of antibiotic-resistant bacteria has led to the development of new antibiotics and alternative therapies, such as antivirals and antifungals. Gilead Sciences is a biopharmaceutical company that develops and markets therapeutics for infectious diseases, including HIV/AIDS, hepatitis B and C, and influenza.
Canada Radiotherapy Market Analysis
Canada radiotherapy market is likely to grow at a CAGR of 6% from a market size of $552.8 Mn in 2022 to $881 Mn in 2030. The rising incidence of cancer and the technological advancements in radiotherapy acts as a market growth driver. This report is segmented by type, technology, application, and by end user. Some key players in this market include Siemens Healthineers, Elekta Accuray Incorporated, Hitachi, IsoRay, Zeiss group, and others.
Canada Liver Diseases Therapeutics Market Analysis
Canada's liver disease therapeutics market is likely to grow at a CAGR of 5.7% from a market size of $1.84 Bn in 2022 to $2.87 Bn in 2030. The increase in alcohol consumption along with the change in lifestyle and increasing geriatric population acts as a market growth driver. This report is segmented by treatment type, disease type, and by distribution channel. Some key players in this market include AbbVie, Novartis, Bristol-Myers & Squibb, Merck, Roche, Eli Lilly, and others.
Canada Cardiovascular Diseases Therapeutics Market Analysis
Canada's cardiovascular disease therapeutics market is likely to grow at a CAGR of 7.22% from a market size of $13.01 Bn in 2022 to $22.72 Bn in 2030. Rising cardiovascular disease prevalence and growing R&D are the major market driver. This report is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and by end users. Some key players in this market include Johnson and Johnson, Gilead, AstraZeneca, Novartis, Roche, Merck, Pfizer, and others.
Canada Cancer Immunotherapy Market Analysis
Canada's cancer immunotherapy market is likely to grow at a CAGR of 7.1% from a market size of $9 Bn in 2022 to $15.58 Bn in 2030. Rising cancer prevalence and growing adoption of immunotherapy are the major market driver. This report is segmented by type, application, and by distribution channel. Some key players in this market include Johnson and Johnson, Eli Lilly, Novartis, Roche, Merck, Pfizer, and others.
Turkey Liver Diseases Therapeutics Market Analysis
By 2030, it is anticipated that the Turkey Liver Disease Therapeutics market will reach a value of $299 Mn from $185 Mn in 2022, growing at a CAGR of 6.2 % during 2022-2030. Liver Disease Therapeutics in Turkey is dominated by a few domestic pharmaceutical companies such as Abdi İbrahim, Mustafa Nevzat, and Deva Holding. The Liver Disease Therapeutics market in Turkey is segmented into different types of disease and different therapy types. Some of the major factors affecting the Turkey Liver Disease Therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.
Saudi Arabia Liver Diseases Therapeutics Market Analysis
By 2030, it is anticipated that the Saudi Arabia Liver Disease Therapeutics market will reach a value of $685 Mn from $393 Mn in 2022, growing at a CAGR of 7.2% during 2022-2030. Liver Disease Therapeutics in Saudi Arabia is dominated by a few domestic pharmaceutical companies such as Tabuk Pharmaceuticals, Jamjoom Pharma, and SPIMACO. The Liver Disease Therapeutics market in Saudi Arabia is segmented into different types of disease and different therapy types. Some of the major factors affecting the Saudi Arabia Liver Disease Therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.
Mexico Liver Diseases Therapeutics Market Analysis
By 2030, it is anticipated that the Mexico Liver Disease Therapeutics market will reach a value of $550 Mn from $346 Mn in 2022, growing at a CAGR of 6 % during 2022-2030. Liver Disease Therapeutics in Mexico is dominated by a few domestic pharmaceutical companies such as Liomont, Laboratorios Senosiain, and Silanes Laboratorios. The Liver Disease Therapeutics market in Mexico is segmented into different types of disease and different therapy types. Some of the major factors affecting the Mexico Liver Disease Therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.
Indonesia Liver Diseases Therapeutics Market Analysis
By 2030, it is anticipated that the Indonesia Liver Disease Therapeutics market will reach a value of $216 Mn from $139 Mn in 2022, growing at a CAGR of 5.7% during 2022-2030. Liver Disease Therapeutics in Indonesia are dominated by a few domestic pharmaceutical companies such as Kalbe Farma, Dexa Medica, and Combiphar. The Liver Disease Therapeutics market in Indonesia is segmented into different types of disease and different therapy types. Some of the major factors affecting the Indonesia Liver Disease Therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.
Germany Cardiovascular Diseases Therapeutics Market Analysis
Germany's cardiovascular disease therapeutics market is expected to witness growth from $5.95 Bn in 2022 to $9.08 Bn in 2030 with a CAGR of 5.42% for the year 2022-2030. Technological advancements and supportive government policies in terms of cardiovascular diseases in Germany are responsible for the growth of the market. The Germany cardiovascular disease therapeutics market is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and by the end user. Waypharm, Cordes Pharma, and Pfizer are the major players in the Germany cardiovascular disease therapeutics market.
